<code id='13BE912F79'></code><style id='13BE912F79'></style>
    • <acronym id='13BE912F79'></acronym>
      <center id='13BE912F79'><center id='13BE912F79'><tfoot id='13BE912F79'></tfoot></center><abbr id='13BE912F79'><dir id='13BE912F79'><tfoot id='13BE912F79'></tfoot><noframes id='13BE912F79'>

    • <optgroup id='13BE912F79'><strike id='13BE912F79'><sup id='13BE912F79'></sup></strike><code id='13BE912F79'></code></optgroup>
        1. <b id='13BE912F79'><label id='13BE912F79'><select id='13BE912F79'><dt id='13BE912F79'><span id='13BE912F79'></span></dt></select></label></b><u id='13BE912F79'></u>
          <i id='13BE912F79'><strike id='13BE912F79'><tt id='13BE912F79'><pre id='13BE912F79'></pre></tt></strike></i>

          Home / fashion / leisure time

          leisure time


          leisure time

          author:entertainment    Page View:97379
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In